Following this puts new work involving it at the top of your briefing, with a note saying why it is there. Links are taken from the source record, never inferred.
A systematic review of 102 AI prediction studies showing that most lack external validation, prospective evidence, or workflow integration; none demonstrate interventional benefit for treatment tailoring in breast cancer neoadjuvant therapy.
A narrative review summarizing current therapeutic indications and their perioperative implications for reconstructive planning; expert synthesis rather than original evidence.
A comprehensive review integrating evidence from trials and biomarker studies to propose a precision immunotherapy framework for TNBC, addressing current standards and unresolved clinical challenges.
A descriptive cross-sectional survey of patient and clinician perspectives on communication and decision-making in advanced breast cancer, without a control group, randomisation, or hard clinical outcomes; it identifies discrepancies and unmet needs but does not test an intervention or establish causal effects.
A systematic review of 10 trials with qualitative synthesis only, reporting descriptive findings about survival disparities without meta-analytic effect sizes, confidence intervals, or quantified comparisons between HER2-low and HER2-positive cohorts.
Real-world observational study confirming efficacy of dual HER2 blockade in neoadjuvant HER2-positive breast cancer, consistent with historical trial data but limited by small single-centre sample and descriptive design.
A narrative review synthesizing randomized trial evidence and recent regulatory approvals to propose a risk-adapted treatment framework for HER2-positive early-stage breast cancer, not reporting original trial data.
Retrospective single-center study of moderate size showing PET/CT parameters independently predict pathological complete response with improved model discrimination, but lacks prospective validation and external generalization.